The coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has killed millions of people worldwide. The current crisis has created an unprecedented demand for rapid test of SARS-CoV-2 infection. Reverse transcription loop-mediated isothermal amplification (RT-LAMP) is a fast and convenient method to amplify and identify the transcripts of a targeted pathogen. However, the sensitivity and specificity of RT-LAMP were generally regarded as inferior when compared with the gold standard RT-qPCR. To address this issue, we combined bioinformatic and experimental analyses to improve the assay performance for COVID-19 diagnosis. First, we developed an improved algorithm to design LAMP primers targeting the nucleocapsid (N), membrane (M), and spike (S) genes of SARS-CoV-2. Next, we rigorously validated these new assays for their efficacy and specificity. Further, we demonstrated that multiplexed RT-LAMP assays could directly detect as low as a few copies of SARS-CoV-2 RNA in saliva, without the need of RNA isolation. Importantly, further testing using saliva samples from COVID-19 patients indicated that the new RT-LAMP assays were in total agreement in sensitivity and specificity with standard RT-qPCR. In summary, our new LAMP primer design algorithm along with the validated assays provide a fast and reliable method for the diagnosis of COVID-19 cases.
Various forms of contact restriction have been adopted in response to the Covid-19 pandemic. Only recently, rapid testing appeared as a new policy instrument. If sufficiently effective, it may serve as a substitute for contact restrictions. Against this background we evaluate the effects of a unique policy experiment: on March 16, the city of Tuebingen set up a rapid testing scheme while relaxing lockdown measures-in sharp contrast to its German peers. Comparing case rates in Tuebingen county to an appropriately defined control unit over a four-week period, we find an increase in the reported case rate, robustly across alternative specifications. However, the increase is temporary and about one half of it reflects cases that would have gone undetected in the absence of extra testing.
SARS-CoV-2, the coronavirus causing COVID-19, has infected and killed several millions of people worldwide. Since the first COVID-19 outbreak in December 2019, SARS-CoV-2 has evolved with a few genetic variants associated with higher infectivity. We aimed to identify polymorphic loci in SARS-CoV-2 that can be used to define and monitor the viral epidemiology and population genetics in different geographical regions. Between December 2019 and September 2020, we sampled 5,959 SARS-CoV-2 genomes. More than 80% of the genomes sampled in Africa, Asia, Europe, North America, Oceania and South America were reportedly isolated from clinical infections in older patients, ≥ 20 years. We used the first indexed genome (NC_045512.2) as a reference and constructed multilocus genotypes (MLGs) for each sampled genome based on amino acids detected at 74 polymorphic loci located in ORF1ab, ORF3a, ORF8, matrix (M), nucleocapsid (N) and spike (S) genes. Eight of the 74 loci were informative in estimating the risk of carrying infections with mutant alleles among different age groups, gender and geographical regions. Four mutant alleles - ORF1ab L4715, S G614, and N K203 and R204 reached 90% prevalence globally, coinciding with peaks in transmission but not COVID-19 severity, from March to August 2020. During this period, the MLG genetic diversity was moderate in Asia, Oceania and North America; in contrast to Africa, Europe and South America, where lower genetic diversity and absence of linkage disequilibrium indicated clonal SARS-CoV-2 transmission. Despite close relatedness to Asian MLGs, MLGs in the global population were genetically differentiated by geographic region, suggesting structure in SARS-CoV-2 populations. Our findings demonstrate the utility of the 74 loci as a genetic tool to study and monitor SARS-CoV-2 transmission dynamics and evolution, which can inform future control interventions.
Although current industry guidelines to control the spread of SARS-CoV-2 (COVID-19) have adopted a six-foot (~1.8m) spacing between individuals indoors, recent evidence suggests that longer range spread is also responsible for infections in public spaces. The vehicle for long-range spread is smaller droplets or particles, termed bio-aerosols, or aerosols for short, which have a large surface area to volume ratio such that aerodynamic drag is much larger than gravity forces. The aerosols remain suspended in air for extended time periods and they essentially move with air currents. Prediction of the danger to occupants in a closed room when exposed to an infected individual requires knowledge of the period of exposure and the concentration level of aerosols in the breathing zone of an occupant. To obtain an estimate of the concentration level, a common assumption is well-mixed conditions within an interior space. This is obtained from a mass balance between the level of aerosol produced by an infected individual along with the airflow rate into and out of the entire space. In this work, we use computational fluid dynamics, verified by experimental results, to explore the aerosol concentration distribution in a typical classroom for several common conditions and compare these results to the well-mixed assumption. We use a tracer gas to simulate the flow and dispersion of the aerosol-air mixture. The two ventilation systems examined, ceiling diffusers and open windows, yield average concentrations at occupant breathing level 50% greater than the well mixed case, and some scenarios yield concentrations that are 150% greater than the well mixed concentration at specific breathing-level locations. Of particular concern are two conditions: horizontal air flow from an open window in line with a row of seating and, second, an infected individual seated near a sealed cold window. For the former, conditions are improved if a baffle is placed inside the open window to direct the air toward the floor, creating a condition similar to displacement ventilation. In the latter, the cold air flowing down along the cold window recirculates aerosols back into the breathing zone. Adding window covers or a portable heater below the window surface will moderate this condition.
Background The long-term sequelae of coronavirus disease 2019 (Covid-19) in children remain poorly characterised. This study aimed to assess long-term outcomes in children previously hospitalised with Covid-19 and associated risk factors. Methods This is a prospective cohort study of children (18 years old and younger) admitted with confirmed Covid-19 to Z.A. Bashlyaeva Children9s Municipal Clinical Hospital in Moscow, Russia. Children admitted to the hospital during the first wave of the pandemic, between April 2, 2020 and August 26, 2020, were included. Telephone interview using the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) Covid-19 Health and Wellbeing paediatric follow up survey. Persistent symptoms (>5 months) were further categorised by system(s) involved. Findings Overall, 518 of 853 (61%) of eligible children were available for the follow-up assessment and included in the study. Median age was 10.4 years (IQR, 3-15.2) and 270 (52.1%) were girls; median follow-up since hospital discharge was 256 (223-271) days. At the time of the follow-up interview 126 (24.3%) participants reported persistent symptoms among which fatigue (53, 10.7%), sleep disturbance (36, 6.9%,) and sensory problems (29, 5.6%) were the most common. Multiple symptoms were experienced by 44 (8.4%) participants. Risk factors for persistent symptoms were: age “6-11 years” (odds ratio 2.74 (95% confidence interval 1.37 to 5.75) and “12-18 years” (2.68, 1.41 to 5.4), and a history of allergic diseases (1.67, 1.04 to 2.67). Interpretation A quarter of children experienced persistent symptoms months after hospitalization with acute covid-19 infection, with almost one in ten experiencing multi-system involvement. Older age and allergic diseases were associated with higher risk of persistent symptoms at follow-up. Our findings highlight the need for replication and further investigation of potential mechanisms as well as clinical support to improve long term outcomes in children. Funding None.
Background: The study aimed to analyze the demographic, comorbidities, biomarkers, pharmacotherapy, and ICU-stay with the mortality outcome of COVID-19 patients admitted in the intensive care unit of a tertiary care hospital in a low-middle income country, Bangladesh. Methods: The retrospective cohort study was done in Holy Family Red Crescent Medical College Hospital from May to September 2020. All 112 patients who were admitted to ICU as COVID-19 cases (confirmed by RT-PCR of the nasopharyngeal swab) were included in the study. Demographic data, laboratory reports of predictive biomarkers, treatment schedule, and duration of ICU-stay of 99 patients were available and obtained from hospital records (non-electronic) and treatment sheets, and compared between the survived and deceased patients. Results: Out of 99 patients admitted in ICU with COVID-19, 72 were male and 27 were female. The mean age was 61.08 years. Most of the ICU patients were in the 60 - 69 years of age group and the highest mortality rates (35.89%) were observed in this age range. Diabetes mellitus and hypertension were the predominant comorbidities in the deceased group of patients. A significant difference was observed in neutrophil count, creatinine and, NLR, d-NLR levels that raised in deceased patients. There was no significant difference as a survival outcome of antiviral drugs remdesivir or favipiravir, while the use of cephalosporin was found much higher in the survived group than the deceased group (46.66% vs 20.51%) in ICU. Conclusions: Susceptibility to developing critical illness due to COVID-19 was found more in comorbid males aged more than 60 years. There were wide variations of the biomarkers in critical COVID-19 patients in a different population, which put the healthcare workers into far more challenge to minimize the mortality in ICU in Bangladesh and around the globe during the peak of the pandemic.
Background: Viral diversity presents an ongoing challenge for diagnostic tests, which need to accurately detect all circulating variants. The Abbott Global Surveillance program monitors severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants and their impact on diagnostic test performance. Objectives: To evaluate the capacity of Abbott molecular, antigen, and serologic assays to detect the SARS-CoV-2 B.1.1.7, B.1.351 and the P.1 variants. Study design: Virus variant culture stock dilutions (B.1.1.7, BEI NR-54011; B.1.351, BEI NR-54008 and 54009; P.1, BEI NR-54982) and clinical samples from patients with confirmed B.1.1.7 variant infection were run on the Abbott ID NOW COVID-19, m2000 RealTime SARS-CoV-2, Alinity m SARS-CoV-2, and Alinity m Resp-4-Plex molecular assays; the BinaxNOW COVID-19 Ag Card and Panbio COVID-19 Ag Rapid Test Device; and the ARCHITECT/Alinity i SARS-CoV-2 IgG and AdviseDx IgM assays, Panbio COVID-19 IgG assay, and ARCHITECT/Alinity i AdviseDx SARS-CoV-2 IgG II assay. Results: Cultured virus stocks and B.1.1.7 clinical samples were detected with molecular, antigen, and serologic assays in the expected ranges, confirming in silico predictions. The ratio between genome equivalents (GE) and calculated median tissue culture infectious dose (TCID50) were 31- to 83-fold higher for B.1.1.7 cultures compared to B.1.351 and P.1 cultures, demonstrating that GE are more consistent units between cultures than TCID50. Conclusions: Abbott molecular and antigen assays effectively detect B.1.1.7, B.1.351, and P.1 variant infections and Abbott serologic assays detect B.1.1.7 antibodies in patient sera. Future studies with SARS-CoV-2 virus cultures should use quantitative viral load values to compare detection of variants.
A major policy tool used by governments during the COVID-19 pandemic has been the imposition of quarantine and testing requirements on international travel, extending even to the extreme approach of closing national borders. However, both approaches have far-reaching socioeconomic implications. Therefore, we evaluated the implications of quarantine and testing compared to the reductions achieved by border closure on in-country imminent transmission based on country-specific prevalence, daily incidence, vaccine coverage, immunity, age-demographics, and travel flow. We considered travel quarantines of 0–14 days with and without RT-PCR or antigen testing for COVID-19 in 31 European countries. Our analysis demonstrates that for the vast majority of origin-destination country pairs, there are combinations of short-duration quarantine and testing that are as effective as border closure. Furthermore, for most origin-destination country pairs, travel with testing and no quarantine will reduce imminent in-country transmission more than would border closure. We find that the duration of quarantine is predominantly influenced by country prevalence and quantity of travel. With higher prevalence in the origin country compared to the destination country, the minimum duration of quarantine increases from zero to beyond fourteen days (at which point border closure would likely be practical). Asymmetry in travel flow can also cause an increase or decrease of infections within the destination country, respectively resulting in longer and shorter quarantines. We apply the same framework to genetic variants of concern to limit their spread as a consequence of travel; the widespread variant of concern B.1.1.7 yields similar sufficient quarantine and testing regimes, whereas the lower-frequency, geographically heterogeneous 501Y.V2 variant requires longer, more specific quarantines. We show that adaptation of our analytical framework to the European Union traffic-light country risk stratification provides a simplified policy tool. Lastly, we examined the effect of travel quarantine and testing or border closure policy on hospitalization in the destination country. We find that hospitalization rates in the destination country are far more sensitive to changes in the vaccine coverage than on the duration of the travel quarantine or the country of origin. Our analysis provides rigorous guidelines enabling travel between most countries during early and late phases of pandemic disease.
Oestrogen Treatment for COVID-19 Symptoms - Condition: COVID-19
Intervention: Drug: Transdermal estradiol gel
Sponsors: Hamad Medical Corporation; Laboratoires Besins International
Not yet recruiting
Virgin Coconut Oil as Adjunctive Therapy for Hospitalized COVID-19 Patients - Condition: Covid19
Intervention: Drug: Virgin Coconut Oil
Sponsors: University of the Philippines; Philippine Coconut Authority; Philippine Council for Health Research & Development
Recruiting
Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19 - Conditions: Covid19; COVID-19 Prevention
Interventions: Drug: Hydroxychloroquine (HCQ); Other: Standard care; Other: Placebo
Sponsor: Postgraduate Institute of Medical Education and Research
Recruiting
Clinical Study in the Treatment of Patients With Moderate Course of COVID-19 - Condition: COVID-19
Interventions: Drug: COVID-globulin; Drug: Placebo
Sponsor: Microgen
Recruiting
Study to Evaluate a Single Dose of LTX-109 in Subjects With COVID-19 (Coronavirus Disease 2019) Infection. - Condition: COVID-19
Interventions: Drug: LTX-109 gel, 3%; Drug: Placebo gel
Sponsors: Pharma Holdings AS; Clinical Trial Consultants AB
Not yet recruiting
Safety and Efficacy of Niclosamide in Patients With COVID-19 With Gastrointestinal Infection - Condition: Covid19
Interventions: Drug: Niclosamide; Drug: Placebo
Sponsor: AzurRx BioPharma, Inc.
Not yet recruiting
A Clinical Study Evaluating Inhaled Aviptadil on COVID-19 - Condition: Covid19
Interventions: Drug: Inhaled Aviptadil; Drug: Placebo
Sponsors: Centurion Pharma; Klinar CRO
Recruiting
ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19 - Condition: Covid19
Interventions: Biological: Remdesivir; Drug: Remdesivir Placebo; Biological: Aviptadil; Drug: Aviptadil Placebo; Drug: Corticosteroid
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); International Network for Strategic Initiatives in Global HIV Trials (INSIGHT); University of Copenhagen; Medical Research Council; Kirby Institute; Washington D.C. Veterans Affairs Medical Center; AIDS Clinical Trials Group; National Heart, Lung, and Blood Institute (NHLBI); US Department of Veterans Affairs; Prevention and Early Treatment of Acute Lung Injury (PETAL); Cardiothoracic Surgical Trials Network (CTSN); NeuroRx, Inc.; Gilead Sciences
Recruiting
COVID-19 Close Contact Self-Testing Study - Condition: Covid19
Interventions: Behavioral: COVID-19 self-test; Behavioral: COVID-19 test referral
Sponsor: University of Pennsylvania
Not yet recruiting
Detection of Covid-19 in Nasopharyngeal Swabs by Using Multi-Spectral Spectrophotometry - Condition: Covid19
Intervention: Diagnostic Test: AP-23
Sponsor: Fable Biyoteknoloji San ve Tic A.S
Recruiting
Safety and Immunogenicity of Demi-dose of Two Covid-19 mRNA Vaccines in Healthy Population - Condition: Covid19
Intervention: Diagnostic Test: immunogenicity after first and second dose
Sponsors: Sciensano; Mensura EDPB; Institute of Tropical Medicine, Belgium; Erasme University Hospital
Not yet recruiting
Remdesivir Efficacy In Management Of COVID-19 Patients - Condition: Covid19
Interventions: Drug: Remdesivir; Drug: Standard of care_1; Drug: Standard of care_2
Sponsor: Ain Shams University
Completed
SLV213 Treatment in COVID-19 Patients - Condition: Covid19
Interventions: Drug: SLV213; Drug: Placebo
Sponsors: Kenneth Krantz, MD, PhD; FHI Clinical, Inc.
Not yet recruiting
Assessment of Efficacy of KAN-JANG® in Mild COVID-19 - Condition: Covid19
Interventions: Drug: Kan Jang capsules; Other: Placebo capsules
Sponsors: Swedish Herbal Institute AB; Tbilisi State Medical University; Phytomed AB
Not yet recruiting
Hydroxychloroquine for Treatment of Non-Severe COVID-19 - Condition: Covid19
Intervention: Drug: Hydroxychloroquine tablets
Sponsor: Makerere University
Active, not recruiting
Overcoming culture restriction for SARS-CoV-2 in human cells facilitates the screening of compounds inhibiting viral replication - Efforts to mitigate the COVID-19 pandemic include screening of existing antiviral molecules that could be re-purposed to treat SARS-CoV-2 infections. Although SARS-CoV-2 replicates and propagates efficiently in African green monkey kidney (Vero) cells, antivirals such as nucleos(t)ide analogs (nucs) often show decreased activity in these cells due to inefficient metabolization. SARS-CoV-2 exhibits low viability in human cells in culture. Here, serial passages of a SARS-CoV-2 isolate…
Plitidepsin, an inhibitor of the cell elongation factor eEF1a, and molnupiravir an analogue of the ribonucleoside cytidine, two new chemical compounds with intense activity against SARS-CoV-2 - The knowledge of the replicative cycle of SARS-CoV-2 and its interactions with cellular proteins has opened a new therapeutic possibility based on blocking those essential for the virus. The cellular protein elongation factor eEF1A could be a good target. Among its natural inhibitors are didemnins and their related chemical compounds such as plitidepsin. In human cell culture, this compound is capable of inhibiting the virus with a potency 27,5 times that of remdesivir. It must be administered…
Synthesis, antioxidant, antimicrobial and antiviral docking studies of ethyl 2-(2-(arylidene)hydrazinyl)thiazole-4-carboxylates - A series of ethyl 2-(2-(arylidene)hydrazinyl)thiazole-4-carboxylates (2a-r) was synthesized in two steps from thiosemicarbazones (1a-r), which were cyclized with ethyl bromopyruvate to ethyl 2-(2-(arylidene)hydrazinyl)thiazole-4-carboxylates (2a-r). The structures of compounds (2a-r) were established by FT-IR, ¹H- and ^(13)C-NMR. The structure of compound 2a was confirmed by HRMS. The compounds (2a-r) were then evaluated for their antimicrobial and antioxidant assays. The antioxidant studies…
N-Glycosylated Ganoderma lucidum immunomodulatory protein improved anti-inflammatory activity via inhibition of the p38 MAPK pathway - The global health emergency generated by coronavirus disease-2019 has prompted the search for immunomodulatory agents. There are many potential natural products for drug discovery and development to tackle this disease. One of these candidates is the Ganoderma lucidum fungal immunomodulatory protein (FIP-glu). In the present study, we clarify the influences of N-linked glycans on the improvement of anti-inflammatory activity and the potential mechanisms of action. Four proteins, including…
nhibition mechanism and hot-spot prediction of nine potential drugs for SARS-CoV-2 M(pro) by large-scale molecular dynamic simulations combined with accurate binding free energy calculations - Coronavirus disease 2019 (COVID-19), which is caused by a new coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading around the world. However, a universally effective treatment regimen has not been developed to date. The main protease (Mpro), a key enzyme of SARS-CoV-2, plays a crucial role in the replication and transcription of this virus in cells and has become the ideal target for rational antiviral drug design. In this study, we performed molecular…
A Rapid, Multiplex Dual Reporter IgG and IgM SARS-CoV-2 Neutralization Assay for a Multiplexed Bead-Based Flow Analysis System - The COVID-19 pandemic has underscored the need for rapid high-throughput methods for sensitive and specific serological detection of infection with novel pathogens, such as SARS-CoV-2. Multiplex serological testing can be particularly useful because it can simultaneously analyze antibodies to multiple antigens that optimizes pathogen coverage, and controls for variability in the organism and the individual host response. Here we describe a SARS-CoV-2 IgG 3-plex fluorescent microsphere-based…
Mucosal immunity to severe acute respiratory syndrome coronavirus 2 infection - PURPOSE OF REVIEW: Despite its crucial role in protection against viral infections, mucosal immunity has been largely understudied in the context of coronavirus disease 2019 (COVID-19). This review outlines the current evidence about the role of mucosal immune responses in the clearance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, as well as potential mucosal mechanisms of protection against (re-)infection.
COVID-19: captures iron and generates reactive oxygen species to damage the human immune system - Currently, the novel coronavirus pneumonia has been widespread globally, and there is no specific medicine. In response to the emergency, we employed bioinformatics methods to investigate the virus’s pathogenic mechanism, finding possible control methods. We speculated in previous studies that E protein was associated with viral infectivity. The present study adopted the domain search techniques to analyse the E protein. According to the results, the E protein could bind iron or haem. The iron…
Manipulation of genes could inhibit SARS-CoV-2 infection that causes COVID-19 pandemics - The year 2020 witnessed an unpredictable pandemic situation due to novel coronavirus (COVID-19) outbreaks. This condition can be more severe if the patient has comorbidities. Failure of viable treatment for such viral infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is due to lack of identification. Thus, modern and productive biotechnology-based tools are being used to manipulate target genes by introducing the clustered regularly interspaced short palindromic…
Structure-Based Virtual Screening to Identify Novel Potential Compound as an Alternative to Remdesivir to Overcome the RdRp Protein Mutations in SARS-CoV-2 - The number of confirmed COVID-19 cases is rapidly increasing with no direct treatment for the disease. Few repurposed drugs, such as Remdesivir, Chloroquine, Hydroxychloroquine, Lopinavir, and Ritonavir, are being tested against SARS-CoV-2. Remdesivir is the drug of choice for Ebola virus disease and has been authorized for emergency use. This drug acts against SARS-CoV-2 by inhibiting the RNA-dependent-RNA-polymerase (RdRp) of SARS-CoV-2. RdRp of viruses is prone to mutations that confer drug…
An Overview of Spike Surface Glycoprotein in Severe Acute Respiratory Syndrome-Coronavirus - The novel coronavirus originated in December 2019 in Hubei, China. This contagious disease named as COVID-19 resulted in a massive expansion within 6 months by spreading to more than 213 countries. Despite the availability of antiviral drugs for the treatment of various viral infections, it was concluded by the WHO that there is no medicine to treat novel CoV, SARS-CoV-2. It has been confirmed that SARS-COV-2 is the most highly virulent human coronavirus and occupies the third position following…
Promising role of curcumin against viral diseases emphasizing COVID-19 management: A review on the mechanistic insights with reference to host-pathogen interaction and immunomodulation - Curcumin has already acknowledged immense interest from both medical and scientific research because of its multifaceted activity. To date, the promising effects of curcumin were perceived against numerous inflammatory diseases. Besides, curcumin’s role as a medicine has been studied in many virus infections like influenza, HIV, etc. There is a need to analyze the cellular mechanisms of curcumin including host-pathogen interaction and immunomodulatory effects, to explore the role of curcumin…
The dual role of the immune system in the course of COVID-19. The fatal impact of the aging immune system - COVID-19 is a highly contagious respiratory disease caused by the novel coronavirus SARS-CoV-2. Since October 2020 the second wave of the pandemic has been observed around the world, as pathogen specific herd immunity has not been built yet. Moreover, the current, more contagious pathogen carrying the D614G mutation has become the globally dominant form of SARS-CoV-2. In this article we present the current state of knowledge on the impact of ACE2 and the reninangiotensin system (RAS) and the…
The effects of COVID-19 continuous traumatic stressors on mental health and cognitive functioning: A case example from Turkey - There is a need to accurately assess the specific impacts of the various traumatic stressors caused by COVID-19 on mental health. The goal was to evaluate the impact of different types of COVID-19 stressors (infection fears, lockdown, and economic stressors) on mental health and cognitive functioning. We used a sample of 262 Turkish adults. We administered an online questionnaire that included measures of COVID-19 traumatic stressors, PTSD, depression, anxiety, executive function deficits, and…
Women as Leaders: Chances and Risks of the COVID-19 Pandemic - The low representation of women in leadership positions has induced the EU Commission to define measures and targets for gender equality. Almost simultaneously, the measures adopted in the coronavirus pandemic have led to profound changes in the organisation of work. These can slow or inhibit the process. This article provides an overview of the situation of women in leadership positions and the most important reasons for their underrepresentation. Special attention is paid to the effects of the…
Compositions and methods for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection - - link
5-(4-TERT-BUTOXY PHENYL)-3-(4N-OCTYLOXYPHENYL)-4,5-DIHYDROISOXAZOLE MOLECULE (C-I): A PROMISING DRUG FOR SARS-COV-2 (TARGET I) AND BLOOD CANCER (TARGET II) - The present invention relates to a method ofmolecular docking of crystalline compound (C-I) with SARS-COV 2 proteins and its repurposing with proteins of blood cancer, comprising the steps of ; employing an algorithmto carry molecular docking calculations of the crystalized compound (C-I); studying the compound computationally to understand the effect of binding groups with the atoms of the amino acids on at least four target proteins of SARS-COV 2; downloading the structure of the proteins; removing water molecules, co enzymes and inhibitors attached to the enzymes; drawing the structure using Chem Sketch software; converting the mol file into a PDB file; using crystalized compound (C-I) for comparative and drug repurposing with two other mutated proteins; docking compound into the groove of the proteins; saving format of docked molecules retrieved; and filtering and docking the best docked results. - link
AQUEOUS ZINC OXIDE NANOSPRAY COMPOSITIONS - Disclosed herein is aqueous zinc oxide nano spray compositions comprising zinc oxide nanoparticles and a synthetic surfactant for controlling the spread of Covid-19 virus. - link
Bettverlängerungssystem (1) für in Bauchlage beatmungspflichtige Patienten in Gestalt mit zumindest einer Platte (16), dadurch gekennzeichnet, dass die Platte (16) im Kopflagerungsbereich einen Luftwegezugangsdurchbruch (8) mit einem den Luftwegezugangsdurchbruch (8) umgebenden Auflagerbereich für ein durchbrochenes Kopfauflagepolster (14) aufweist, durch den von der Bettunterseite her und durch das Kopfauflagepolster (14) hindurch die Ver- und Entsorgungsschläuche für eine orotracheale Intubation oder eine nasotracheale Intubation ventral an das Gesicht des Patienten herangeführt werden können, und dass die Platte (16) im Bereich ihrer dem Kopfende eines Bettrosts (15) zugeordneten Stirnseite (6) ein Fixierelement (2) zur Befestigung der Platte (16) am Bettrost (15) nach Art eines einseitig frei über das Kopfende des Bettrosts hinausragenden Kragträgers aufweist.
一种肝素类药物组合物、喷鼻剂及其制备方法及应用 - 本发明公开了一种肝素类药物组合物、喷鼻剂及其制备方法及应用。该肝素类药物组合物包括肝素钠和阿比朵尔。本发明中的肝素类药物组合物首次采用肝素钠和阿比朵尔联合使用，普通肝素钠联合1μM/L以上的阿比朵尔病毒抑制效率显著高于单独普通肝素钠或单独阿比多尔组（p<0.05）。 - link
USING CLINICAL ONTOLOGIES TO BUILD KNOWLEDGE BASED CLINICAL DECISION SUPPORT SYSTEM FOR NOVEL CORONAVIRUS (COVID-19) WITH THE ADOPTION OF TELECONFERENCING FOR THE PRIMARY HEALTH CENTRES/SATELLITE CLINICS OF ROYAL OMAN POLICE IN SULTANATE OF OMAN - - link
抗SARS-COV-2中和抗体 - 本公开提供了针对SARS‑COV‑2的新颖中和抗体和其抗原结合片段。还提供了包括其的药物组合物和试剂盒以及其用途。 - link
Peptides and their use in diagnosis of SARS-CoV-2 infection - - link
Method and compositions for treating coronavirus infection - A method of treating viral infection, such as viral infection caused by a virus of the Coronaviridae family, is provided. A composition having at least oleandrin is used to treat viral infection. - link
Luftreinigungssäule (1) mit einer Luftaufnahme (2) und einer Luftausgabe (3), wobei zwischen der Luftaufnahme (2) und der Luftausgabe (3) ein luftleitender Bereich (4) mit einem Gebläse (7) und einer UV-Lichtdesinfektionseinrichtung (5) angeordnet ist, dadurch gekennzeichnet, dass der luftleitende Bereich (4) photokathalysatorisch beschichtete Oberflächen (9) aufweist und/oder ein photokathalysatorisch beschichtetes Gitter (11) angeordnet ist, wobei photokathalysatorisch beschichtetes Gitter (11) und die photokathalysatorisch beschichtete Oberflächen (9) mit Titandioxid (TiO2) beschichtet sind, wobei die UV-Lichtdesinfektionseinrichtung (5) UV-A-LEDs (12), die UV-A-Strahlung im Wellenlängenbereich 380-315 nm ausstrahlt und UV-C-LEDs (8) die UV-Strahlung im Wellenlängenbereich UV-C 280-200 nm (8) ausstrahlen aufweist und wobei ein Akku (13) zur netzunabhängigen Stromversorgung angeordnet ist.